Method for treating non-melanoma skin cancer by inducing UDP-glucuronosyltransferase activity using pterostilbene

Patent metadata

Field	Value
Publication number	US-10039725-B2
Application number	US-201414493058-A
Country	US
Kind code	B2
Filing date	Sep 22, 2014
Priority date	May 11, 2011
Publication date	Aug 7, 2018
Grant date	Aug 7, 2018

Abstract

A method is provided for treating an individual for a cellular proliferative disorder, including administering to the individual in need of such treatment a therapeutically effective amount of the compound pterostilbene wherein UDP-glucuronosyltransferase (UGT) activity is increased. In an embodiment, 12-HETE levels can be reduced by administration of pterostilbene.

First claim

We claim:

1. A method of treating an individual for a non-melanoma skin cancer, comprising administering to the individual in need of such treatment a therapeutically effective amount of the compound pterostilbene provided in a composition wherein UDP-glucuronosyltransferase (UGT) activity is increased, and wherein the therapeutically effective amount of pterostilbene for a total dose is in a range of about 0.1% by weight to about 10% by weight based on the total weight of the composition.

2. The method of claim 1 , wherein the individual is a human.

3. The method of claim 2 , wherein the pterostilbene compound is provided in a composition comprising a pharmaceutically or nutraceutically acceptable carrier.

4. The method of claim 3 , wherein the therapeutically effective amount of pterostilbene for a total dose is in a range of about 0.1% by weight to about 0.5% by weight based on the total weight of the composition.

5. The method of claim 3 , wherein the therapeutically effective amount of pterostilbene for a total daily dose is in a range of about 5 mg to about 1000 mg.

6. The method of claim 3 , wherein the therapeutically effective amount of pterostilbene for a total daily dose is in a range of about 50 mg to about 250 mg.

7. The method of claim 5 , wherein the route of administration of the compound is selected from the group consisting of oral, topical, intradermal, transdermal, and subcutaneous.

8. The method of claim 1 , wherein the non-melanoma skin cancer is selected from the group consisting of basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, Merkel cell carcinoma, and cutaneous lymphoma.

9. The method of claim 8 , wherein the non-melanoma skin cancer is squamous cell carcinoma.

10. The method of claim 9 , further wherein 12-HETE levels are reduced in the squamous cell carcinoma.

11. The method of claim 1 , further wherein 12-HETE levels are reduced in the non-melanoma skin cancer.

12. A method of inhibiting UV-induced loss of UDP-glucuronosyltransferase (UGT) activity in an individual afflicted with a non-melanoma skin cancer, comprising administering to the individual in need of such treatment a therapeutically effective amount of the compound pterostilbene provided in a composition wherein UDP-glucuronosyltransferase (UGT) activity is increased, and wherein the therapeutically effective amount of pterostilbene for a total dose is in a range of about 0.1% by weight to about 10% by weight based on the total weight of the composition.

13. The method of claim 12 , wherein the individual is a human.

14. The method of claim 13 , wherein the pterostilbene compound is provided in a composition comprising a pharmaceutically or nutraceutically acceptable carrier.

15. The method of claim 14 , wherein the therapeutically effective amount of pterostilbene for a total dose is in a range of about 0.1% by weight to about 0.5% by weight based on the total weight of the composition.

16. The method of claim 14 , wherein the therapeutically effective amount of pterostilbene for a total daily dose is in a range of about 5 mg to about 1000 mg.

17. The method of claim 14 , wherein the therapeutically effective amount of pterostilbene for a total daily dose is in a range of about 50 mg to about 250 mg.

18. The method of claim 16 , wherein the route of administration of the compound is selected from the group consisting of oral, topical, intradermal, transdermal, and subcutaneous.

19. The method of claim 12 , wherein the non-melanoma skin cancer is selected from the group consisting of basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, Merkel cell carcinoma, and cutaneous lymphoma.

20. The method of claim 19 , wherein the non-melanoma skin cancer is squamous cell carcinoma.

21. The method of claim 20 , further wherein 12-HETE levels are reduced in the squamous cell carcinoma.

22. The method of claim 12 , further wherein 12-HETE levels are reduced in the non-melanoma skin cancer.

Assignees

• Chromadex Inc
• Univ California
• The Regents Of The Unviersity Of California

Inventors

• Bartos Jeremy
• Dellinger Ryan

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P19/08

  for bone diseases, e.g. rachitism, Paget's disease · CPC title